Allelic variation in the vitamin D receptor was the first non-structural gene to be associated with osteoporosis, and together with the effects of the vitamin D system on bone homeostasis, suggested that this vitamin might have a strong role in bone health. However, controversy exists regarding what level of serum 25-hydroxyvitamin D (25(OH)D) is optimal. Current data from biochemical, observational and randomized controlled trials (RCTs), indicate serum 25(OH)D levels of at least 50 nmol l À 1 are required for normalization of parathyroid hormone (PTH) levels, to minimize the risk of osteomalacia and for optimal bone cell function. The skeletal consequences of 25(OH)D insufficiency include secondary hyperparathyroidism, increased bone turnover and bone loss and an increased risk of minimal trauma fractures. In large scale epidemiological studies, serum 25(OH)D levels are associated with bone mineral density in both men and women. However, there is mixed evidence on the effectiveness of optimizing serum 25(OH)D levels for the prevention of bone loss and minimal trauma fractures in postmenopausal women and older men. There may be some benefit on primary fracture prevention for those who have inadequate serum levels of 25(OH)D, particularly in institutionalised elderly patients, but only when combined with calcium supplements. For optimal bone health, evidence from RCTs suggests vitamin D may be considered a threshold nutrient with few further bone benefits observed at levels of 25(OH)D above which PTH is normalized. An adequate calcium intake is also imperative to gain optimum benefit from an improved vitamin D status in those with insufficient 25(OH)D levels, with an increased calcium intake being associated with suppression of PTH levels. A large, multicentre, genome-wide association study of 15 cohorts, comprising about 30 000 white people from European descent, found that polymorphisms at three different loci involved in vitamin D metabolism affect serum 25(OH)D levels and the risk of vitamin D deficiency. 4 After accounting for age, sex, body mass index and season, polymorphisms in at least three, and perhaps four loci, influenced serum 25(OH)D levels: (1) 4p12 polymorphisms near or within the GC gene, which encodes vitamin D binding protein, the main transporter of vitamin D metabolites in the blood; (2) 11q12 polymorphisms near DHCR7/NADSYN1, encoding the enzyme 7-dehydrocholesterol reductase, which converts 7-dehydrocholesterol into cholesterol in the skin thereby removing the substrate for production of vitamin D 3 ; (3) 11p15 polymorphisms near CYP2R1, which encodes an enzyme responsible for 25-hydroxylation of vitamin D in the liver; (4) CYP24A1 encoding 24-hydroxylase, which initiates degradation of 25(OH)D and 1,25(OH) 2 D. Participants with a genotype score (combining the three main variants) in the top quartile had twice the risk of having vitamin D insufficiency (o50 or 75 nmol l À 1 ) than those in the lowest quartile. It was also associated with a 1.5-fold risk of severe vitamin D deficiency (o2...